Treatment
Paclitaxel + Carboplatin clinical trials
We’re tracking 239 recruiting studies that include Paclitaxel + Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT06575322Recruiting
Neoadjuvant therapy for head and neck cancer: effects on pain and mood
This trial tests whether adding immunotherapy to chemotherapy before surgery can help reduce pain, anxiety, and depression in people with head and neck cancer. The goal is to see if this approach improves quality of life during treatment.
Guanzhou, GuangdongAges 18–80 - NCT06492759RecruitingPhase 2
High-dose radiation with pembrolizumab and chemo for pd-l1 positive tnbc
This trial tests giving high-dose radiation along with the immunotherapy drug pembrolizumab and chemo to people with a specific subtype of advanced breast cancer (PD-L1 positive triple negative). It may help shrink tumors and keep them from growing.
Atlanta, GeorgiaAges 18 years+ - NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT04192253RecruitingPhase 2
Carboplatin and paclitaxel before surgery for vulvar cancer
This trial tests giving chemotherapy (carboplatin and paclitaxel) before surgery for certain cases of squamous cell vulvar cancer. It may help shrink the tumor and make surgery more effective.
AmsterdamAges 18 years+ - NCT07266493RecruitingPhase 2
Envafolimab plus chemo for esophageal cancer before surgery
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04253964RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced lung cancer
This study tests a combination of chemotherapy and immunotherapy in people with advanced non-small cell lung cancer that has spread or cannot be removed with surgery. The goal is to see how well this treatment works in patients with different levels of daily activity.
Winston-Salem, North CarolinaAges 18 years+ - NCT06969612RecruitingPhase 1
New drug combo as first treatment for advanced lung cancer
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07131319RecruitingPhase 2/Phase 3
Combination therapy for advanced lung cancer
This trial tests a new treatment combining stereotactic radiation (SFRT), the immunotherapy tislelizumab, and platinum chemotherapy for people with stage III non-small cell lung cancer that can't be removed with surgery. It aims to see if this combination helps shrink or control the cancer better.
Nanchang, JiangxiAges 18–85 - NCT04136782RecruitingPhase 4
Tests two chemo drug combinations for triple-negative breast cancer
This Phase 4 trial compares two chemotherapy combinations to treat stage II–III triple-negative breast cancer. It looks for which regimen works better and is tolerated in people with measurable tumors and good overall health.
Harbin, HeilongjiangAges 18–70 - NCT04807140RecruitingPhase 2
Study of toripalimab before surgery for head and neck cancer
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
Guangzhou, GuangdongAges 18–80 - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Hot Springs, ArkansasAges 18 years+ - NCT07221474RecruitingPhase 2
Study of a personalized vaccine plus chemo for lung cancer
This trial tests an experimental personalized cancer vaccine (V940) combined with pembrolizumab and chemotherapy for people with advanced squamous non-small cell lung cancer that has spread. The goal is to see if adding the vaccine helps the immune system fight the cancer better.
Tampa, FloridaAges 18 years+ - NCT06692738RecruitingPhase 3
Is a new immunotherapy better than Keytruda for squamous lung cancer?
This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda), both combined with chemotherapy, as a first treatment for advanced squamous non-small cell lung cancer. It aims to see which combination works better.
Tucson, ArizonaAges 18 years+ - NCT06422143RecruitingPhase 3
Keytruda with or without Sac-TMT for advanced squamous lung cancer
This trial tests the combination of pembrolizumab (Keytruda) with or without a new drug, sacituzumab tirumotecan (Sac-TMT), as initial treatment for advanced squamous non-small cell lung cancer. It aims to see if adding Sac-TMT after initial treatment helps keep cancer under control longer.
Little Rock, ArkansasAges 18 years+ - NCT06731907RecruitingPhase 2
Keytruda with or without chemo for advanced lung cancer
This trial tests a new combination of drugs (Keytruda with or without chemotherapy) to see if it works better for advanced lung cancer. It's for people who haven't had immunotherapy or chemotherapy for their cancer that has spread.
Lexington, KentuckyAges 18 years+ - NCT07662395RecruitingPhase 2/Phase 3
New drug plus chemo for advanced squamous lung cancer
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
Guangzhou, GuangdongAges 18 years+ - NCT07336979RecruitingPhase 2
Chemo plus immunotherapy before surgery for mucosal melanoma
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05800587RecruitingPhase 2
Reduced-dose chemotherapy for advanced lung cancer
This trial studies a lower (reduced) dose of chemotherapy in people with advanced lung cancer who may not tolerate standard treatment. It aims to see if the treatment still works while being safer for “compromised” patients.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06561685RecruitingPhase 1
Study of LY4050784 for Advanced Solid Tumors with SMARCA4 Changes
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
Santa Monica, CaliforniaAges 18 years+ - NCT07647094RecruitingEarly Phase 1
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT06741644RecruitingPhase 1/Phase 2
CS2009 for advanced solid tumors
This trial tests a new drug called CS2009 for people with advanced solid tumors that haven't responded to other treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT05000892RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for salivary cancer
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
Guangzhou, GuangdongAges 18–80 - NCT05019716RecruitingPhase 1/Phase 2
Adding ZEN003694 to chemo for NUT cancer
This early-phase study tests whether adding ZEN003694 to standard chemotherapy (cisplatin/etoposide or carboplatin/paclitaxel) is safe and can help control NUT carcinoma. It enrolls people ages 12–17 and adults, including some patients whose cancer has spread or can’t be safely removed.
Los Angeles, CaliforniaAges 12 years+ - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+
Common questions
- Are there clinical trials studying Paclitaxel + Carboplatin?
- Yes. Clin2 currently lists 239 recruiting studies that include Paclitaxel + Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Paclitaxel + Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Paclitaxel + Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Paclitaxel + Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.